Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATIC
REST API REST API
Homo sapiens
ATIC is differentially expressed in 290 experiments: 96 organism parts: kidney, blood, ... (94 more);, 204 disease states: normal, acute promyelocytic leukemia, ... (202 more);, 108 cell types 292 cell lines 29 compound treatments and 70 other conditions.
Synonyms PURH, AICARFT, IMPCHASE
Orthologs Atic (Rattus norvegicus)   Q5XKY5_CHICK (Gallus gallus)   Atic (Mus musculus)   ADE17 (Saccharomyces cerevisiae)   ADE16 (Saccharomyces cerevisiae)   atic (Danio rerio)   PUR9_BOVIN (Bos taurus)   ENSCING00000004059 (Ciona intestinalis)   CG11089 (Drosophila melanogaster)   atic (Xenopus laevis)   ATIC (Canis familiaris)   (Compare orthologs)
Gene Ontology Term IMP cyclohydrolase activity, cytosol, phosphoribosylaminoimidazolecarboxamide formyltransferase activity, purine ribonucleoside monophosphate biosynthetic process, purine nucleotide biosynthetic process, transferase activity, protein homodimerization activity, hydrolase activity, purine base metabolic process, catalytic activity, mitochondrion, organ regeneration, nucleobase-containing compound metabolic process, nucleobase-containing small molecule metabolic process
InterPro Term AICARFT_IMPCHas, MGS-like_dom
Gene-Disease Assocation AICAR TRANSFORMYLASE/IMP CYCLOHYDROLASE DEFICIENCY
UniProt Accession P31939, C9JLK0, F5GWY2, E9PBU3, F2Z3E8, F8WEF0
Search EB-eye ENSG00000138363
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MEXP-433, E-MTAB-25, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HepG2
2
E-GEOD-21154, E-MTAB-37
NA19127
1
E-GEOD-19480
286 more value(s).


Cell type

studied in E-GEOD-20677, E-GEOD-2822, E-TABM-34, E-GEOD-3998, E-GEOD-995, ... (50 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
macrophage
1
2
E-GEOD-8286, E-GEOD-5099, E-GEOD-360
embryonic stem cell
1
E-MEXP-930
mesendoderm/endoderm progenitor cell
1
E-MEXP-930
102 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-TABM-15, ... (56 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-96, E-MTAB-62, E-GEOD-995
colon carcinoma
3
E-MTAB-62, E-MTAB-57, E-GEOD-3726
lung adenocarcinoma
3
E-GEOD-2514, E-MEXP-231, E-MTAB-62
prostate carcinoma
3
E-GEOD-96, E-MTAB-62, E-MEXP-1327
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
E-MTAB-37, E-MTAB-62
198 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-6907, E-TABM-782, E-GEOD-5824, ... (20 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
4,5-dianilinophthalimide
1
1
E-GEOD-5258
interleukin-22 (Homo sapiens)
1
E-GEOD-7216
Cxcl12
1
E-GEOD-7307
baseline sevoflurane
1
E-GEOD-4386
ethanol
1
E-MEXP-2241
23 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-MTAB-62 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, E-GEOD-6431, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-22056, E-GEOD-1045, E-GEOD-17476, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-TABM-127, E-GEOD-20540, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-GEOD-1926, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.47 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM